DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines

References

[1] Appelbaum FR, Rowe JM, Radich J, et al. Acute myeloid leukemia. N Engl J Med 1999;341:1051–1062.

[2] Bruno PM, Liu Y, Park GY, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 2017;23:461–471.

[3] Ebrahem Q, Mahfouz RZ, Ng KP, et al. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 2012;3:1137–1145.

[4] Fugger K, Bajrami I, Dos Santos MS, et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 2021;372:156–165.

[5] Jamieson GP, Finch LR, Snook M, et al. Degradation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in human leukemic myeloblasts and lymphoblasts. Cancer Res 1987;47:3130–3135.

[6] Jiang H, Pritchard JR, Williams RT, et al. A mammalian functional- genetic approach to characterizing cancer therapeutics. Nat Chem Biol 2011;7:92–100.

[7] Lin YW, Slape C, Zhang Z, et al. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005;106:287–295.

[8] Maley GF, Maley F. The significance of the substrate specificity of T2r+-induced deoxycytidylate deaminase. J Biol Chem 1966;241:2176–2177.

[9] Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007;3:807–817.

[10] Scarano E. The enzymatic deamination of 6-aminopyrimidine deoxyribonucleotides. I. The enzymatic deamination of deoxycytidine 5′-phosphate and of 5-methyldeoxycytidine 5- methyldeoxycytidine 5′-phosphate. J Biol Chem 1960a;235:706–713.

[11] Scarano E. The enzymatic deamination of 6-aminopyrimidine deoxyribonucleotides. II. Purification and properties of a 6-aminopyrimidine deoxyribonucleoside 5′-phosphate deaminase from unfertilized eggs of sea urchine. J Biol Chem 1960b;235:706–713.

[12] Vilpo JA, Vilpo LM. Nucleoside monophosphate kinase may be the key enzyme preventing salvage of DNA 5-methylcytosine. Mutat Res-Fund Mol M 1993;286:217–220.

[13] Wang L, Gural A, Sun XJ, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011;333:765–769.

[14] Wang T, Yu H, Hughes NW, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras. Cell 2017;168:890–903.e15e815.

[15] Zauri M, Berridge G, Thézénas ML, et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 2015;524:114–118.

RIGHTS & PERMISSIONS

The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.